Biomarkers.

Alzheimers Dement

Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Published: December 2024

Background: Physical activity (PA) is associated with increased release of brain derived neurotrophic factor (BDNF), a mechanism that may underlie protective effects of PA on cognitive and brain aging. The Met allele of the BDNF Val66Met single-nucleotide polymorphism reduces activity-dependent BDNF release and is associated with increased phosphorylated tau (p-tau181) in dementia populations. We sought to determine whether BDNF Val66Met influences the effects of PA on plasma p-tau181 and cognition in older adults without dementia.

Method: 123 older adults from the UCSF Memory and Aging Center completed blood draw assayed for p-tau181 (Quanterix Simoa), BDNF Val66Met (rs6265) genotyping (Sequenom), 30-days of Fitbit actigraphy monitoring, and comprehensive neuropsychological evaluation (M = 73.93; SD = 8.88, 59% female, 42% Met-allele carriers). Habitual PA levels were operationalized via average daily step count. Composite z-scores were calculated for cognitive domains of memory and executive functioning. Linear regression was used to determine the moderating effect of BDNF genotype on the relationship between PA and plasma p-tau181. Moderated mediation analyses subsequently examined the consequences of this moderation effect on cognitive outcomes.

Result: Average PA, plasma p-tau181, and cognitive z-scores did not differ between Met-allele carriers and Val/Val participants. BDNF genotype moderated the relationship between PA and plasma p-tau181 (b = 0.18, p = 0.036), whereby higher PA was associated with lower plasma p-tau181 concentrations in Val/Val participants only (Figure 1). In moderated mediation analyses examining cognitive outcomes, plasma p-tau181 concentration mediated the relationship between PA and executive function for Val/Val participants only (index of mod-med = -0.037, p = 0.031; Figure 2). Models examining memory did not reach statistical significance.

Conclusion: Findings converge with prior studies highlighting BDNF release as a potential mechanism underlying the neuroprotective effects of physical activity, including lower AD pathological burden and better cognition. These results further elucidate sources of individual variation observed in the effects of PA on the brain in older adults. Future work should further examine the molecular pathways bridging the effects of the BDNF Val66Met polymorphism on PA-related benefits for brain aging to guide personalized neurotrophic treatments in older adults.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.092836DOI Listing

Publication Analysis

Top Keywords

plasma p-tau181
24
bdnf val66met
16
older adults
16
val/val participants
12
bdnf
9
physical activity
8
associated increased
8
brain aging
8
bdnf release
8
p-tau181
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Turner Institute for Brain and Mental Health & School of Psychological Sciences, Monash University, Clayton, VIC, Australia.

Background: Plasma and cerebrospinal (CSF) biomarkers are promising candidates for detecting neuropathology. While CSF biomarkers directly reflect pathophysiological processes within the central nervous system, their requirement for a lumbar puncture is a barrier to their widespread scalability in practice. Therefore, we examined cross-sectional associations of plasma biomarkers of amyloid (Aβ42/Aβ40 and pTau-181), neurodegeneration (Neurofilament Light, NfL), and neuroinflammation (Glial Fibrillary Acidic Protein, GFAP) with brain volume, cognition, and their corresponding CSF levels.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Xiangya Hospital, Central South University, Changsha, Hunan, China.

Background: Existing biomarkers including cerebrospinal fluid and positron emission tomography for Alzheimer's disease (AD) diagnosis are relatively invasive and expensive. Application of exhaled breath collection and volatile organic compound (VOC) detection for AD diagnosis remains unclear.

Method: In this cross-sectional study, high-pressure photon ionization time-of-flight mass spectrometry (HPPI-ToF-MS) was used to detect VOCs from breath in three datasets and patients diagnosed as Parkinson's disease (PD).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China.

Background: Previous studies have found that AD-related plasma markers are associated with Aβ deposition, but the specific effects remain unclear.

Method: Data were obtained from the Longitudinal Study of Cognitive Decline in China (SILCODE). Comprehensive neuropsychological assessments, MRI, plasma samples, and amyloid positron-emission tomography (Aβ-PET) data were collected.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Clinical Memory Research Unit, Lund University, Lund, Sweden.

Background: Fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non-disease related average signal (inter-individual variability), which can reduce the precision of concentration based CSF AD biomarkers. Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.

View Article and Find Full Text PDF

Background: Recent reports support the use of plasma biomarkers of neurodegeneration and neuroinflammation, as determined through ultrasensitive single molecular arrays (SIMOA), to screen and diagnose patients with dementia. However, their translation to clinical settings requires further studies.

Methods: We evaluated plasma samples from 186 individuals including 72 patients with AD (supported by CSF biomarkers consistent with an A+T+N+ classification scheme), 44 with confirmed FTD, 48 cognitively intact nonagenarians, and 22 controls (ages 40-83 years).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!